Insmed Incorporated
INSM
Rank in Stocks
#1108
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Share Price
$95.65
Last synced: 2026-10-19
Market Cap
$20.89B
Change (1 day)
-0.65%
Change (1 year)
-43.04%
Country
US
Trade Insmed Incorporated (INSM)
Category
Healthcare
Number of shares outstanding for Insmed Incorporated (INSM)
Number of shares outstanding as of June 2026: 217.35M
According to Insmed Incorporated latest financial reports and stock price the company's current number of shares outstanding is 217.35M. At the end of December 2023 the company had 140.43M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Insmed Incorporated (INSM) from 2000 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 217.35M | 32.50% |
| 2024 | 164.04M | 16.81% |
| 2023 | 140.43M | 14.14% |
| 2022 | 123.04M | 9.74% |
| 2021 | 112.11M | 14.86% |
| 2020 | 97.61M | 15.43% |
| 2019 | 84.56M | 10.04% |
| 2018 | 76.84M | 15.42% |
| 2017 | 66.58M | 7.64% |
| 2016 | 61.85M | 5.72% |
| 2015 | 58.51M | 35.99% |
| 2014 | 43.02M | 22.99% |
| 2013 | 34.98M | 31.89% |
| 2012 | 26.52M | 13.59% |
| 2011 | 23.35M | 76.21% |
| 2010 | 13.25M | 4.24% |
| 2009 | 12.71M | 4.08% |
| 2008 | 12.21M | 6.49% |
| 2007 | 11.47M | 20.31% |
| 2006 | 9.53M | 95.56% |
| 2005 | 4.87M | 24.47% |
| 2004 | 3.92M | 10.00% |
| 2003 | 3.56M | 7.66% |
| 2002 | 3.31M | 0.59% |
| 2001 | 3.29M | 79.44% |
| 2000 | 1.83M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 16.82% |
US
|
|
| 396.00M | 82.19% |
US
|
|
| 478.91M | 120.34% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -71.39% |
NL
|
